PE20070708A1 - Formulacion en aerosol para inhalacion de beta-agonistas - Google Patents
Formulacion en aerosol para inhalacion de beta-agonistasInfo
- Publication number
- PE20070708A1 PE20070708A1 PE2006001218A PE2006001218A PE20070708A1 PE 20070708 A1 PE20070708 A1 PE 20070708A1 PE 2006001218 A PE2006001218 A PE 2006001218A PE 2006001218 A PE2006001218 A PE 2006001218A PE 20070708 A1 PE20070708 A1 PE 20070708A1
- Authority
- PE
- Peru
- Prior art keywords
- hydroxy
- alkyl
- ethyl
- halogen
- salts
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000443 aerosol Substances 0.000 title abstract 2
- 229940125388 beta agonist Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- LXWXXYJYGJKFOI-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methylpropan-2-amine Chemical compound CCC1=CC=C(CC(C)(C)N)C=C1 LXWXXYJYGJKFOI-UHFFFAOYSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 1
- -1 METANSULPHONATE Chemical compound 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical class CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIERE A UNA FORMULACION EN AEROSOL SIN GAS PROPELENTE QUE COMPRENDE:A) UN COMPUESTO DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C4, O-(ALQUILO C1-C4), HALOGENO; R2 ES H, ALQUILO C1-C4, HALOGENO, O-(ALQUILO C1-C4); R3 ES H, HALOGENO, OH, -O-ALQUILEN C1-C4-COOH, ENTRE OTROS; X ES ANION DE CARGA NEGATIVA SIMPLE SELECCIONADO ENTRE CLORURO, BROMURO, YODURO, METANSULFONATO, NITRATO, MALEATO; ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-HIDROXI-8-{1-HIDROXI-2-[2-(ESTER ETILICO DEL ACIDO 4-FENOXI-ACETICO)-1,1-DIMETIL-ETILAMINO]ETIL}-4H-BENZO[1,4]OXAZIN-3-ONA; 8-{2-[2-(4-ETILO-FENIL)-1,1-DIMETIL-ETILAMINO]-1-HIDROXI-ETIL}-6-HIDROXI-4H-BENZO[1,4]OXAZIN-3-ONA; ENTRE OTROS. B) OTRO PRINCIPIO ACTIVO SELECCIONADO ENTRE SALES DE OXITROPIO, SALES DE TIOTROPIO, SALES DE GLUCOPIRRONIO, ENTRE OTROS. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES DE LAS VIAS RESPIRATORIAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05109376 | 2005-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070708A1 true PE20070708A1 (es) | 2007-08-06 |
Family
ID=35241312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001218A PE20070708A1 (es) | 2005-10-10 | 2006-10-06 | Formulacion en aerosol para inhalacion de beta-agonistas |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20070088030A1 (es) |
| EP (1) | EP1940349B1 (es) |
| JP (1) | JP2009511542A (es) |
| KR (1) | KR20080059290A (es) |
| CN (1) | CN101282712A (es) |
| AR (1) | AR058082A1 (es) |
| AU (1) | AU2006301330B9 (es) |
| BR (1) | BRPI0617278A2 (es) |
| CA (1) | CA2624786C (es) |
| CY (1) | CY1120199T1 (es) |
| DK (1) | DK1940349T3 (es) |
| EA (1) | EA200800927A1 (es) |
| EC (1) | ECSP088294A (es) |
| ES (1) | ES2668364T3 (es) |
| HR (1) | HRP20180713T1 (es) |
| HU (1) | HUE039186T2 (es) |
| IL (1) | IL190682A (es) |
| LT (1) | LT1940349T (es) |
| MY (1) | MY163503A (es) |
| NO (1) | NO343363B1 (es) |
| NZ (1) | NZ567545A (es) |
| PE (1) | PE20070708A1 (es) |
| PL (1) | PL1940349T3 (es) |
| PT (1) | PT1940349T (es) |
| RS (1) | RS57085B1 (es) |
| SI (1) | SI1940349T1 (es) |
| TW (1) | TWI389692B (es) |
| UA (1) | UA99250C2 (es) |
| UY (1) | UY29844A1 (es) |
| WO (1) | WO2007042468A2 (es) |
| ZA (1) | ZA200801390B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US20050272726A1 (en) * | 2004-04-22 | 2005-12-08 | Boehringer Ingelheim International Gmbh | Novel medicaments for the treatment of respiratory diseases |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
| US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
| CN101208316B (zh) * | 2005-08-15 | 2012-05-09 | 贝林格尔·英格海姆国际有限公司 | 制备β-模拟物的方法 |
| US20110281858A1 (en) * | 2008-11-21 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta agonists |
| US20110319402A1 (en) * | 2008-11-21 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta agonists |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| WO2014016548A2 (en) | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| WO2014056840A1 (en) * | 2012-10-09 | 2014-04-17 | Boehringer Ingelheim International Gmbh | Beta-2-adrenoceptor agonist for the treatment of cough |
| US20140235627A1 (en) * | 2012-12-21 | 2014-08-21 | Boehringer Ingelheim International Gmbh | ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| SG10201912198WA (en) * | 2015-05-18 | 2020-02-27 | Glenmark Specialty Sa | Tiotropium inhalation solution for nebulization |
| JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
| US20210322311A1 (en) * | 2020-04-16 | 2021-10-21 | Cai Gu Huang | Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol |
| CN115703121A (zh) * | 2021-08-07 | 2023-02-17 | 广州谷森制药有限公司 | 一种含噻托溴铵、奥达特罗药品制剂和除醛包材容器的组合 |
| CN114259481A (zh) * | 2021-11-26 | 2022-04-01 | 南京华盖制药有限公司 | 一种奥达特罗复方吸入溶液 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3134590A1 (de) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue benzo-heterocyclen |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| WO1994013263A1 (en) * | 1992-12-09 | 1994-06-23 | Jager Paul D | Stabilized medicinal aerosol solution formulations |
| NZ522677A (en) * | 2000-04-27 | 2004-10-29 | Boehringer Ingelheim Pharma | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
| DE10216036A1 (de) | 2002-04-11 | 2003-10-23 | Boehringer Ingelheim Pharma | Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz |
| DE10253282A1 (de) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US7244728B2 (en) * | 2004-03-17 | 2007-07-17 | Boehringer Ingelheim International Gmbh | Long acting betamimetics for the treatment of respiratory diseases |
| US20050272726A1 (en) * | 2004-04-22 | 2005-12-08 | Boehringer Ingelheim International Gmbh | Novel medicaments for the treatment of respiratory diseases |
| US20050239778A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
| EA013157B1 (ru) * | 2004-04-22 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей |
| US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
| US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
| US7220742B2 (en) * | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
-
2006
- 2006-10-05 US US11/543,477 patent/US20070088030A1/en not_active Abandoned
- 2006-10-05 TW TW095137046A patent/TWI389692B/zh active
- 2006-10-06 AU AU2006301330A patent/AU2006301330B9/en active Active
- 2006-10-06 CN CNA2006800377251A patent/CN101282712A/zh active Pending
- 2006-10-06 HR HRP20180713TT patent/HRP20180713T1/hr unknown
- 2006-10-06 AR ARP060104405A patent/AR058082A1/es not_active Application Discontinuation
- 2006-10-06 CA CA2624786A patent/CA2624786C/en not_active Expired - Fee Related
- 2006-10-06 PE PE2006001218A patent/PE20070708A1/es not_active Application Discontinuation
- 2006-10-06 ES ES06807028.3T patent/ES2668364T3/es active Active
- 2006-10-06 MY MYPI20081057A patent/MY163503A/en unknown
- 2006-10-06 LT LTEP06807028.3T patent/LT1940349T/lt unknown
- 2006-10-06 UY UY29844A patent/UY29844A1/es not_active Application Discontinuation
- 2006-10-06 KR KR1020087011009A patent/KR20080059290A/ko not_active Ceased
- 2006-10-06 BR BRPI0617278-4A patent/BRPI0617278A2/pt not_active Application Discontinuation
- 2006-10-06 PT PT68070283T patent/PT1940349T/pt unknown
- 2006-10-06 HU HUE06807028A patent/HUE039186T2/hu unknown
- 2006-10-06 EA EA200800927A patent/EA200800927A1/ru unknown
- 2006-10-06 RS RS20180434A patent/RS57085B1/sr unknown
- 2006-10-06 DK DK06807028.3T patent/DK1940349T3/en active
- 2006-10-06 SI SI200632255T patent/SI1940349T1/en unknown
- 2006-10-06 WO PCT/EP2006/067126 patent/WO2007042468A2/de not_active Ceased
- 2006-10-06 NZ NZ567545A patent/NZ567545A/en unknown
- 2006-10-06 EP EP06807028.3A patent/EP1940349B1/de active Active
- 2006-10-06 JP JP2008535001A patent/JP2009511542A/ja active Pending
- 2006-10-06 UA UAA200805249A patent/UA99250C2/ru unknown
- 2006-10-06 PL PL06807028T patent/PL1940349T3/pl unknown
-
2008
- 2008-02-11 ZA ZA200801390A patent/ZA200801390B/xx unknown
- 2008-02-14 NO NO20080801A patent/NO343363B1/no unknown
- 2008-03-19 EC EC2008008294A patent/ECSP088294A/es unknown
- 2008-04-08 IL IL190682A patent/IL190682A/en active IP Right Grant
-
2009
- 2009-09-22 US US12/564,477 patent/US20100009984A1/en not_active Abandoned
-
2011
- 2011-04-14 US US13/087,009 patent/US20110190284A1/en not_active Abandoned
-
2018
- 2018-05-10 CY CY20181100484T patent/CY1120199T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070708A1 (es) | Formulacion en aerosol para inhalacion de beta-agonistas | |
| PE20081319A1 (es) | Formulacion de aerosol para la inhalacion de agonistas beta | |
| PE20080607A1 (es) | Formulacion en aerosol para la inhalacion de beta-agonistas | |
| ES2298993T3 (es) | Nuevos agonistas beta-2-de efecto prolongado y su uso como medicamentos. | |
| ES2826562T3 (es) | Solución para inhalación de tiotropio por nebulizador | |
| PE20071250A1 (es) | Formulaciones farmaceuticas que comprenden pleconaril | |
| NO20066041L (no) | Anvendelse av substituerte kinolinderivater for behandlingen og legemiddelresistente mykobakterielle sykdommer | |
| PE20030823A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
| PE20060239A1 (es) | Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonista enantiomericamente puros | |
| JP6373867B2 (ja) | Ｌｆａ−１阻害剤製剤 | |
| AR038644A1 (es) | Formulaciones hfa de agonistas beta-2 de derivados de 2 (1h)-quinolinona de accion prolongada | |
| JP2009543860A5 (es) | ||
| PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| ECSP055970A (es) | Uso de palonosetron para el tratamiento de nausea y vomito post operatorio | |
| JP2018530578A (ja) | 組み合せ抗細菌組成物および短期抗細菌レジメン | |
| ES2353404T3 (es) | Nuevas combinaciones de medicamentos para el tratamiento de enfermedades de las vías respiratorias. | |
| AU2018263059A1 (en) | Compositions and treatment procedures for the treatment of pathogenic infections | |
| CA2427583C (en) | Inhalable formulation of a solution containing a tiotropium salt | |
| AR081642A1 (es) | Derivados 5,6-dihidro-4-[(difluor-etil)fenil]-4h-pirrolo[1,2-a][1,4]benzodiacepina y 4-(difluoretil)fenil-6h-pirrolo[1,2-a][1,4]benzodiacepina antifungales y composiciones farmaceuticas que los contienen | |
| PE20081358A1 (es) | Combinaciones farmacologicas para el tratamiento de enfermedades de la vias aereas | |
| PE20060311A1 (es) | Formulacion en aerosol para la inhalacion de beta-agonistas | |
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| ES2527055T3 (es) | Formulaciones de compuestos 2-amino-1,3-propanodiol | |
| WO2007007832A1 (ja) | 眼科用防腐組成物 | |
| AR038764A1 (es) | Formulacion de una solucion de inhalacion con una sal de tiotropio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |